Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
107.62
-2.08 (-1.90%)
At close: Mar 28, 2025, 4:00 PM
107.00
-0.62 (-0.58%)
After-hours: Mar 28, 2025, 5:30 PM EDT

Ligand Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Cash & Equivalents
72.3122.9545.0119.5247.62
Upgrade
Short-Term Investments
183.86147.36166.86321.59363.57
Upgrade
Cash & Short-Term Investments
256.17170.31211.87341.11411.19
Upgrade
Cash Growth
50.41%-19.62%-37.89%-17.04%-61.57%
Upgrade
Accounts Receivable
38.3832.9230.4285.4556.85
Upgrade
Other Receivables
4.076.44.616.192.22
Upgrade
Receivables
42.4539.3135.0491.6559.06
Upgrade
Inventory
14.1123.9713.2927.3326.49
Upgrade
Prepaid Expenses
1.931.181.13--
Upgrade
Restricted Cash
----0.34
Upgrade
Other Current Assets
16.92.662.274.673.48
Upgrade
Total Current Assets
331.56237.43263.6464.75500.56
Upgrade
Property, Plant & Equipment
24.8125.0627.4932.637.17
Upgrade
Long-Term Investments
10.9149.323--
Upgrade
Goodwill
105.25103.37105.67105.67189.66
Upgrade
Other Intangible Assets
266.65299.61352.64386.8606.31
Upgrade
Long-Term Accounts Receivable
185.0262.29---
Upgrade
Long-Term Deferred Tax Assets
0.070.218.5335.7324.32
Upgrade
Other Long-Term Assets
17.519.921.74272.034.27
Upgrade
Total Assets
941.77787.22762.671,2981,362
Upgrade
Accounts Payable
5.232.435.318.43.78
Upgrade
Accrued Expenses
25.5310.0913.312.415.61
Upgrade
Current Portion of Long-Term Debt
--76.7--
Upgrade
Current Portion of Leases
1.290.410.721.418.48
Upgrade
Current Income Taxes Payable
1.2----
Upgrade
Current Unearned Revenue
1.281.220.360.6529.44
Upgrade
Other Current Liabilities
2.582.632.4318.842.8
Upgrade
Total Current Liabilities
37.1116.7898.8141.67100.11
Upgrade
Long-Term Debt
---320.72442.29
Upgrade
Long-Term Leases
5.865.7710.342.315.76
Upgrade
Long-Term Unearned Revenue
18.1815.140.04--
Upgrade
Long-Term Deferred Tax Liabilities
32.5231.6230.6230.8664.6
Upgrade
Other Long-Term Liabilities
17.6516.9825.3780.8840
Upgrade
Total Liabilities
111.3486.3165.18476.43652.76
Upgrade
Common Stock
0.020.020.020.020.02
Upgrade
Additional Paid-In Capital
337.38198.7147.59372.97318.36
Upgrade
Retained Earnings
498.98503.02450.86449.09391.95
Upgrade
Comprehensive Income & Other
-5.94-0.82-0.98-0.92-0.8
Upgrade
Total Common Equity
830.44700.91597.49821.16709.53
Upgrade
Shareholders' Equity
830.44700.91597.49821.16709.53
Upgrade
Total Liabilities & Equity
941.77787.22762.671,2981,362
Upgrade
Total Debt
7.156.1887.75324.44456.53
Upgrade
Net Cash (Debt)
249.01164.13124.1216.66-45.34
Upgrade
Net Cash Growth
51.72%32.23%644.83%--
Upgrade
Net Cash Per Share
13.619.247.360.97-2.69
Upgrade
Filing Date Shares Outstanding
19.2617.7117.0816.8516.61
Upgrade
Total Common Shares Outstanding
19.1117.5616.9516.7716.08
Upgrade
Working Capital
294.45220.65164.79423.09400.45
Upgrade
Book Value Per Share
43.4639.9235.2548.9744.13
Upgrade
Tangible Book Value
458.54297.94139.18328.69-86.45
Upgrade
Tangible Book Value Per Share
24.0016.978.2119.60-5.38
Upgrade
Machinery
8.727.7815.1614.3415.72
Upgrade
Construction In Progress
4.224.12---
Upgrade
Leasehold Improvements
10.4610.367.455.273.52
Upgrade
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q